{"id":7718,"date":"2023-03-13T18:09:35","date_gmt":"2023-03-13T17:09:35","guid":{"rendered":"https:\/\/www.ab-science.com\/?p=7718"},"modified":"2023-03-13T18:11:41","modified_gmt":"2023-03-13T17:11:41","slug":"ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i","status":"publish","type":"post","link":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/","title":{"rendered":"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_column_text]<\/p>\n<h3 class=\"Default\">13\/03\/2023 \u2013\u00a0AB Science rapporte aujourd\u2019hui un cas issu de la phase initiale de son \u00e9tude de Phase I\/II (AB18001) \u00e9valuant AB8939, un d\u00e9stabilisateur de microtubules, chez les patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA) r\u00e9fractaire et r\u00e9currente<\/h3>\n<h3 class=\"Default\"><\/h3>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<iframe width=\"100%\" height=\"800\" src=\"https:\/\/www.ab-science.com\/themencode-pdf-viewer-sc\/?tnc_pvfw=ZmlsZT1odHRwczovL3d3dy5hYi1zY2llbmNlLmNvbS93cC1jb250ZW50L3VwbG9hZHMvMjAyMy8wMy9DUC1BQjg5MzktVkZSLVZGLnBkZiZzZXR0aW5ncz0xMTEwMTExMTExMTExMTExMTAwJmxhbmc9ZW4tVVM=#page=&zoom=100&pagemode=none\" title=\"\"><\/iframe>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">#default-btn-2d38432741f6635fb93474373967f9a2.ico-right-side > i {\n  margin-right: 0px;\n  margin-left: 8px;\n}\n#default-btn-2d38432741f6635fb93474373967f9a2 > i {\n  margin-right: 8px;\n}<\/style><div class=\"btn-align-center\"><a href=\"https:\/\/www.ab-science.com\/wp-content\/uploads\/2023\/03\/CP-AB8939-VFR-VF.pdf\" class=\"default-btn-shortcode dt-btn dt-btn-l link-hover-off  vc_custom_1678726433971\" target=\"_blank\" id=\"default-btn-2d38432741f6635fb93474373967f9a2\" rel=\"noopener\"><i class=\"dt-icon-the7-download\"><\/i><span>T\u00e9l\u00e9charger le PDF<\/span><\/a><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text] 13\/03\/2023 \u2013\u00a0AB Science rapporte aujourd\u2019hui un cas issu de la phase initiale de son \u00e9tude de Phase I\/II (AB18001) \u00e9valuant AB8939, un d\u00e9stabilisateur de microtubules, chez les patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb (LMA) r\u00e9fractaire et r\u00e9currente [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[132],"tags":[],"class_list":["post-7718","post","type-post","status-publish","format-standard","hentry","category-2023-fr","category-132","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)<\/title>\n<meta name=\"description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)\" \/>\n<meta property=\"og:description\" content=\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-13T17:09:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-13T17:11:41+00:00\" \/>\n<meta name=\"author\" content=\"Alexis BERNARD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alexis BERNARD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/\"},\"author\":{\"name\":\"Alexis BERNARD\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\"},\"headline\":\"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\\\/II avec AB8939 (AB18001)\",\"datePublished\":\"2023-03-13T17:09:35+00:00\",\"dateModified\":\"2023-03-13T17:11:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/\"},\"wordCount\":187,\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"articleSection\":[\"2023\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/\",\"name\":\"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\\\/II avec AB8939 (AB18001)\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2023-03-13T17:09:35+00:00\",\"dateModified\":\"2023-03-13T17:11:41+00:00\",\"description\":\"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\\\/II avec AB8939 (AB18001)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/person\\\/f22e8dbe9aaad0d416cbea66ecc4a755\",\"name\":\"Alexis BERNARD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g\",\"caption\":\"Alexis BERNARD\"},\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/author\\\/abernard\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/","og_locale":"fr_FR","og_type":"article","og_title":"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)","og_description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","og_url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/","og_site_name":"AB Science","article_published_time":"2023-03-13T17:09:35+00:00","article_modified_time":"2023-03-13T17:11:41+00:00","author":"Alexis BERNARD","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Alexis BERNARD","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/#article","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/"},"author":{"name":"Alexis BERNARD","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755"},"headline":"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)","datePublished":"2023-03-13T17:09:35+00:00","dateModified":"2023-03-13T17:11:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/"},"wordCount":187,"publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"articleSection":["2023"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/","url":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/","name":"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2023-03-13T17:09:35+00:00","dateModified":"2023-03-13T17:11:41+00:00","description":"AB Science annonce aujourd\u2019hui avoir re\u00e7u l\u2019autorisation de l\u2019Agence de Sant\u00e9 Su\u00e9doise pour initier une \u00e9tude de Phase III (AB20009","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/ab-science-annonce-une-premiere-reponse-complete-de-la-moelle-osseuse-chez-un-patient-atteint-de-leucemie-myeloide-aigue-refractaire-en-rechute-a-tres-faible-dose-dans-son-essai-clinique-de-phase-i\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"AB Science annonce une premi\u00e8re r\u00e9ponse compl\u00e8te de la moelle osseuse chez un patient atteint de leuc\u00e9mie my\u00e9lo\u00efde aigue r\u00e9fractaire en rechute, \u00e0 tr\u00e8s faible dose, dans son essai clinique de phase I\/II avec AB8939 (AB18001)"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]},{"@type":"Person","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/person\/f22e8dbe9aaad0d416cbea66ecc4a755","name":"Alexis BERNARD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/586e211c7d685fdd3428b70716f97574cf1b3149b055c1be5bdc5a7306e419bd?s=96&d=mm&r=g","caption":"Alexis BERNARD"},"url":"https:\/\/www.ab-science.com\/fr\/author\/abernard\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=7718"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/posts\/7718\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=7718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/categories?post=7718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/tags?post=7718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}